AirSculpt Technologies, Inc. (AIRS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals significant challenges: a 15% revenue decline, financial control issues, and a high debt level. Although there is some margin expansion and positive signs in body sculpting trends, the overall financial health is concerning. The Q&A section suggests cautious optimism for future revenue but lacks strong positive catalysts. Given these factors, the stock is likely to experience a negative reaction in the short term.
Key Financial Performance
Revenue for Q4 2025 $33.4 million, down approximately 15% year-over-year. The decline reflects lower case volume amidst a challenging consumer spending environment.
Same-store revenue for Q4 2025 Declined 16% year-over-year. This decline is attributed to lower case volume.
Cost of services for Q4 2025 $13.7 million, a decrease of $3.1 million or 18% year-over-year. This contributed to a gross margin expansion of roughly 2% to approximately 59%.
Selling, General and Administrative (SG&A) expenses for Q4 2025 Approximately $18.2 million, a decline of approximately $5 million year-over-year. The decline was primarily due to cost initiatives taken throughout 2025.
Customer acquisition cost for Q4 2025 Roughly $3,300 per case, flat compared to the prior year quarter.
Adjusted EBITDA for Q4 2025 $2.5 million or 7.4% of revenue, an increase of $0.6 million and 2.8% margin expansion year-over-year. This was driven by gross margin expansion and operational leverage in SG&A.
Full-year revenue for 2025 $151.8 million, a decrease of approximately 15.8% year-over-year. The decline reflects lower case volume amidst a challenging consumer spending environment.
Full-year adjusted EBITDA for 2025 Approximately $15 million, resulting in an adjusted EBITDA margin of approximately 10%. This compares to adjusted EBITDA of approximately $21 million or an adjusted EBITDA margin of 12% in fiscal 2024.
Cash flow from operations for 2025 $3.1 million, compared to $11.4 million in fiscal 2024. The decline reflects lower revenue and adjusted EBITDA.
Debt repayment in 2025 $19 million, including $14 million on the term loan and $5 million on the revolving credit facility. Gross debt outstanding was $56 million at year-end.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Services for GLP-1 Market Opportunity: Introduced new services targeting the GLP-1 market, including skin tightening, contour restoration, and skin removal procedures. These services align with the growing demand for aesthetic procedures post-weight loss. Skin removal procedures were piloted in Q4 2025, with over 100 surgeries completed, and are expected to expand across all locations in 2026.
Market Potential Expansion: The skin tightening and skin removal market is estimated to be as large as fat removal, representing a $100 million-plus sales opportunity long-term. Marketing efforts have been deployed to raise awareness of these new services.
Operational Improvements: Implemented a new go-to-market strategy, enhanced marketing efforts, and improved business processes. Marketing enhancements included connected TV, influencer engagement, and optimized website functionality. These efforts contributed to improved lead and consult volumes, as well as revenue trends.
Cost Reduction and Financial Discipline: Reduced costs by $4 million annually in 2025 and repaid over $30 million of debt over the last five quarters, bringing leverage below 2.5x. Simplified operations by exiting the only clinic outside North America.
Strategic Shifts: Focused on stabilizing the business and achieving positive same-store sales growth. Strengthened the balance sheet through equity issuance and debt reduction. Added experienced executives in finance, legal, and operations to support growth initiatives.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Consumer Spending Environment: Revenue for the quarter declined by approximately 15% compared to the prior year, attributed to lower case volume amidst a challenging consumer spending environment.
Helium Plasma Supply Disruption: A meaningful portion of the global helium plasma supply is currently offline due to the Iran conflict, which could impact the company's ability to perform skin tightening procedures.
Debt and Financial Leverage: The company has a significant amount of debt, with gross debt outstanding at $56 million at year-end. Although efforts are being made to reduce debt, financial leverage remains a concern.
Accounting and Financial Controls: Issues were identified in financial processes, including reconciliation matters and lease accounting errors, which led to corrections in prior year balances. This highlights weaknesses in financial controls.
Revenue Decline and Market Competition: Revenue for the full year decreased by approximately 15.8% compared to fiscal 2024, reflecting challenges in maintaining market share and competitive pressures.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: In 2026, the company expects revenue in the range of $151 million to $157 million, reflecting approximately 3% comparable growth excluding the London center from 2025.
Adjusted EBITDA Projections: Fiscal 2026 adjusted EBITDA is expected to be in the range of $15 million to $17 million, incorporating improved revenue growth and annualized cost actions from 2025.
Same-Store Sales: Same-store sales are expected to be flat in Q1 2026, with broad-based improvement in revenue across centers as the year progresses.
Market Opportunity: The GLP-1 market opportunity is expected to drive demand for aesthetic procedures such as skin tightening and contour restoration, representing a $100 million-plus sales opportunity long term.
New Procedures: Skin removal procedures, introduced in Q4 2025, are expected to ramp up in 2026 as the capability expands across all locations.
Capital Allocation: The company plans to refinance its term loan before it becomes current, targeting a net debt leverage ratio below 2.5x.
De Novo Openings: No new center openings are planned for 2026, with a focus on revenue growth in the existing base.
Helium Plasma Supply: The company is monitoring the global helium plasma supply situation closely due to the Iran conflict and will manage the business accordingly.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is causing the slight decline in Q1 revenues year-over-year while full-year 2026 revenue is expected to increase?
A:The CEO explained that the company is being measured in its guidance. Trends have improved meaningfully, and the trajectory has shifted from negative in 2022-2024 to positive comps. The company is focused on consistent execution to meet its numbers.
Q:Can you provide insights into body sculpting trends outside of GLP-1-related procedures and the market trends for the core business?
A:The CEO stated that the core business around body contouring and fat removal is holding steady. The aesthetics industry experienced a boom post-COVID and is now finding a baseline. GLP-1s are seen as the next wave of change, and the company is well-positioned to address demand arising from skin laxity.
Q:What feedback have you received from customers and surgeons regarding the excisional procedures pilot, and how will this inform the broader launch?
A:The CEO mentioned that early signs from the pilot are encouraging, with patients achieving good results and surgeons being comfortable and effective with the procedures. The company plans to ramp up the rollout after evaluating results over a few months and making necessary adjustments.
Q:What is the company's approach to capital allocation, particularly regarding debt paydown and leverage ratio?
A:The CFO stated that the priority is maintaining a healthy balance sheet. The company has reduced its leverage ratio to 2.5x and is in early stages of refinancing debt. The capital allocation strategy focuses on reinvesting in the business, including sales, marketing, and eventually expanding the clinic portfolio.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses provided sufficient detail and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CFO
GLP market
London
Skin removal
accounting
action
addition
aesthetic
brand
capability
capital allocation
correction
day
decline period
delay filing
discipline capital
effort
facility debt
lease
level
margin expansion
midpoint
momentum
opportunity term
progress priority
review
sale marketing
service GLP
skin removal
talent process
term loan
term value
tightening skin
transaction
turnaround
volume trend
weight loss
work
AIRS Transcript
AirSculpt Technologies, Inc. (AIRS) Q4 2025 Earnings Call Transcript
Unknown4-2
The earnings call reveals significant challenges: a 15% revenue decline, financial control issues, and a high debt level. Although there is some margin expansion and positive signs in body sculpting trends, the overall financial health is concerning. The Q&A section suggests cautious optimism for future revenue but lacks strong positive catalysts. Given these factors, the stock is likely to experience a negative reaction in the short term.
AirSculpt Technologies, Inc. (AIRS) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents a negative outlook, with reduced revenue guidance, declining financial performance, and high leverage limiting flexibility. Despite some cost-cutting measures, the revenue and EBITDA have decreased, and the company faces challenges with new services. The Q&A highlighted uncertainties in cost savings and service expansion, with management providing vague responses. Given these factors, a negative stock price movement is likely, reflecting the company's current financial struggles and market uncertainties.
AirSculpt Technologies, Inc. (AIRS) Q2 2025 Earnings Call Transcript
Unknown8-1
The earnings call summary shows a challenging macro environment with a decline in same-store revenue and cases, despite some cost reductions and improved cash flow. The Q&A section highlights consumer hesitancy, uncertainty in revenue guidance, and lack of clear data on new initiatives like skin tightening. The leverage ratio improvement is positive, but overall, weak financial performance and guidance uncertainty suggest a negative sentiment.
AirSculpt Technologies, Inc. (NASDAQ:AIRS) Q1 2025 Earnings Call Transcript
Unknown5-3
The earnings call reveals significant challenges, including a 17.3% revenue decline, increased customer acquisition costs, and financial leverage concerns. Despite some cost savings and potential future improvements, the current negative consumer environment and reduced marketing spend are impacting performance. The lack of a share repurchase program and avoidance of direct answers in the Q&A further contribute to a negative sentiment. Although there are plans for cost savings and improvements, the immediate outlook remains challenging, leading to a predicted negative stock price movement.
AIRS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
